Publications by authors named "C Hulin"

Claim this Profile
P
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.
Françoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman, Aurore Perrot, Cyrille Hulin

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.
Cathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, Sabrin Tahri, Davine Hofste Op Bruinink, Cyrille Hulin

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.
Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Cyrille Hulin

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette, Léo Caillot

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis